Evaluation of aniline mustard in patients with multiple myeloma.
Evaluation of aniline mustard in patients with multiple myeloma.
复制标题
苯胺芥子气对多发性骨髓瘤患者的评价。
作者：
R. Kyle;G. Costa;M. Cooper;M. Ogawa;R. Silver;O. Glidewell;J. Holland
苯胺芥是一种对BALB/c小鼠浆细胞肿瘤有效的烷化剂，用于44例多发性骨髓瘤患者的前瞻性随机研究。这些患者中没有人接受过化疗，只有3人接受过放疗。患者随机分为两个治疗方案，一个是苯胺芥，1 mg/kg，另一个是苯胺芥，1 mg/kg，加泼尼松，1.2 mg/kg，剂量递减。33例患者接受了30天或更长时间的治疗，有资格进行缓解评价。9例患者在两个或更多参数中有应答。除3名患者外，所有患者的骨髓瘤均在研究期间进展。31例缓解中有22例发生在除苯胺芥外还接受泼尼松的患者中。大约三分之二的反应发生在治疗的前60天。毒性主要包括白细胞减少症。10名患者发生感染，另外2名患者出现皮疹。苯胺氮芥对多发性骨髓瘤有一定活性，但不如美法仑。
Summary Aniline mustard, an alkylating agent effective in plasma cell tumors in BALB/c mice, was used in a prospective randomized study of 44 patients with multiple myeloma. None of the patients had received prior chemotherapy, and only three had had radiation. The patients were randomized between two regimens, one consisting of aniline mustard, 1 mg/kg, and the other of aniline mustard, 1 mg/kg, plus prednisone, 1.2 mg/kg in decreasing dosage. Thirty-three patients were treated for 30 days or more and were eligible for evaluation of response. Nine patients responded in two or more parameters. Myeloma progressed during the study in all but three patients. Twenty-two of the 31 responses occurred in patients who received prednisone in addition to aniline mustard. Approximately two-thirds of the responses occurred in the first 60 days of therapy. Toxicity consisted mainly of leukopenia. Infections occurred in 10 patients, and a skin rash was noted in 2 others. Aniline mustard possesses some activity in multiple myeloma but is inferior to melphalan.